Follicular lymphoma research: an open dialogue for a collaborative roadmap

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma, originating from germinal center B cells.
• FL exhibits significant clinical, prognostic, and biological heterogeneity, complicating patient management.
• Despite advances in immunotherapy, a complete understanding and cure for FL remain elusive.

Purpose of the Study:

• To highlight the complexity and heterogeneity of follicular lymphoma.
• To propose a collaborative roadmap for advancing the understanding and treatment of FL.
• To serve as an interactive platform for FL research and clinical care.

Main Methods:

• This review synthesizes current knowledge on FL biology, clinical presentation, and treatment.
• It identifies gaps in understanding and proposes a collaborative approach involving multiple stakeholders.
• The review leverages recent advances in investigative and drug technologies, alongside big data management.

Main Results:

• FL's heterogeneity presents a significant challenge to developing curative and tailored therapies.
• Current understanding of FL is incomplete, with many research questions remaining.
• A collaborative, multi-stakeholder approach is essential to overcome existing bottlenecks.

Conclusions:

• A unified, collaborative roadmap is needed to address the complexities of FL.
• Enhanced understanding of FL heterogeneity will facilitate the development of targeted therapies.
• Continued collaboration among clinicians, researchers, and drug developers is crucial for improving FL patient care and outcomes.